Article
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Breast cancer research : BCR - 3 Feb 2020
Zundelevich Adi, Dadiani Maya, Kahana-Edwin Smadar, Itay Amit, Sella Tal, Gadot Moran, Cesarkas Karen, Farage-Barhom Sarit, Saar Efrat Glick, Eyal Eran, Kol Nitzan, Pavlovski Anya, Balint-Lahat Nora, Dick-Necula Daniela, Barshack Iris, Kaufman Bella, Gal-Yam Einav Nili
Abstract excerpt
BACKGROUND: Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10-50%) in metastatic, endocrine therapy-resistant cancers and are associated with a shorter progression-free survival. Little is known about the incidence and clinical implication of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.